Gastrointestinal stromal tumor, NOS
The term gastrointestinal stromal tumour (GIST) is used for a specific group of tumours comprising the majority of gastrointestinal mesenchymal tumours, including those previously termed leiomyoma, cellular leiomyoma, leiomyoblastoma and leiomyosarcoma
Hamilton SR, Aaltonen LA (Eds.)
. Rare cases involving tissues outside the gastrointestinal tract have also been reported (extragastrointestinal gastrointestinal stromal tumors).
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System.
IARC Press: Lyon 2000
Approximately 60% of GISTs arise in the stomach
Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG (2005)
; they are the most common primary mesenchymal tumour of the gastrointestinal tract GIST spans a clinical spectrum from benign to malignant; it has been estimated that about 25% of gastric GISTs (not counting minimal incidental tumours) are clinically malignant. The median age at manifestation is 60-65 years. GIST are KIT-expressing and KIT signaling-driven mesenchymal tumors respond favourably to treatment with the KIT tyrosine kinase inhibitor imatinib mesylate / gleevec
Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
Cancer 103: 821-9
Druker BJ (2004)
Imatinib as a paradigm of targeted therapies.
Adv Cancer Res 91: 1-30